| Issue | Blueprint Recommendations | Party | Action Steps | Milestones |
|---|---|---|---|---|
| **Lowering List Prices** | Call on the FDA to **evaluate the inclusion of list prices in direct-to-consumer advertising**. | FDA | FDA has formed a working group to determine if it has the authority to require list prices of drugs to be included in consumer advertising. | |
| | Direct CMS to **make Medicare and Medicaid prices more transparent, hold drug makers accountable for their price increases, highlight drugs that have not taken price increases, and recognize when competition is working with an updated drug pricing dashboard.** This tool will also provide patients, families, and caregivers with additional information to make informed decisions and predict their cost sharing. | CMS | CMS has released several information products that provide greater transparency on spending for drugs in the Medicare and Medicaid programs. The dashboards focus on average spending per dosage unit and change in average spending per dosage unit over time. The tools also include additional manufacturer-level drug spending information as well as consumer-friendly descriptions of the drug uses and clinical indications. | |
| | | CMS | CMS proposed to require direct-to-consumer television advertisements of prescription drugs and biological products for which payment is available through or under Medicare or Medicaid to include the Wholesale Acquisition Cost of that drug or biological product. | + Released 10/18/18<br>+ Comments due 12/17/2018 |
| | | | S.3680 would have required CMS to establish reference prices for all Medicare covered drugs and prohibit Medicare payment rates from exceeding those reference prices. | + Introduced 11/29/18<br>+ Referred to HELP Cmte 11/29/18<br>+ Needs to be reintroduced |
| | | | S.3702 / H.R. 7217 would have required drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. | + Referred to Finance Cmte on 12/4/18<br>+ Needs to be reintroduced |
| | | | H.Con.Res 146 expressed the sense of Congress that HHS has the authority to require direct-to-consumer television advertisements of prescription drugs and biological products to include the Wholesale Acquisition Cost of that drug or biological product under sections 1102 and 1871 of the Social Security Act; and that the proposed rule by HHS, through CMS, published in the Federal Register on October 18, 2018, shall be codified without change when finalized. | + Introduced 12/20/18<br>+ Referred to House E&C and W&M 12/20/18<br>+ Needs to be reintroduced |
| | | | HHS Proposed a rule that would eliminate safe harbor protections for certain rebates and discounts under Part D while providing new safe harbor protections for certain reductions made at the point-of-sale as well as for PBM service fees. HHS believes these changes will | + Released 2/6/19<br>+ Comments due 4/8/19 |
| | Develop proposals related to the ACA's **Maximum Rebate Amount provision**, which limits manufacturer rebates on brand and generic drugs in the Medicaid program to 100 percent of the Average Manufacturer Price. | | | |